The encouraging body of evidence competing GnRH analogues and breast cancer prognosis has led to the search and development of association drugs linking GnRH analogues with doxorubicin: AN-152 (also known as AEZS-108) proved to be effective in animal models and relatively safe to be tested in phase II and III trials [16,17]. The gene discussed is GNRH1; the disease is breast carcinoma.